Legend Biotech (LEGN) reported Q3 loss Tuesday of $0.34 per diluted share, wider than the loss of $0.17 a year earlier.
Two analysts surveyed by Capital IQ expected a loss of $0.58.
Revenue for the quarter ended Sept. 30 was $160.2 million, compared with $96.0 million a year earlier.
Analysts surveyed by Capital IQ expected $146.1 million.
As of Sept. 30, the company said it had cash, cash equivalents and time deposits of about $1.2 billion, expected to provide financial runway into 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments